research use only
Cat.No.S3712
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Inhibitors | Berberine BTZ043 Racemate Teicoplanin Ornidazole Skatole Berberine Sulfate Pipemidic acid Ceftiofur PBTZ169 Aminothiazole |
|
In vitro |
DMSO
: 100 mg/mL
(124.05 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 806.08 | Formula | C41H79N3O12 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 217500-96-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(CNC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O | ||
| In vitro |
Tulathromycin A is a macrolide antibiotic that inhibits bacterial protein synthesis (IC50 = 0.26 µM) by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.
|
|---|---|
| In vivo |
In cattle and swine, tulathromycin is characterized by a rapid rate of absorption and large systemic availability after subcutaneous (s.c.) and intramuscular (i.m.) administration. In contrast, oral administration of tulathromycin, using a compounded formulation, has a lower systemic availability (~50%). In plasma, tulathromycin has a long terminal half-life, ranging across species from ~2 to ~5 days except in mice in which the terminal half-life is <20 h. The longest terminal half-life in plasma is seen in foals (~140 h). Lung pharmacokinetic studies in cattle, pigs, horses, and mice show that tulathromycin accumulates in lung tissue. In general, tulathromycin is absorbed rapidly and extensively after parenteral administration. Recent published data generated in pigs, cattle and horses show that tulathromycin also accumulates rapidly and extensively in the intra-airway compartment (PELF, BELF, and cells).
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.